The National Primary Health Care Development Agency (NPHCDA) has received 10,000 doses of the JYNNEOS vaccine to strengthen Nigeria’s mpox response.
Muyi Aina, the executive director of NPHCDA, acknowledged the vaccine donation by the American government on Tuesday in Abuja, noting that it signified more than just the acquisition of medical supplies.
JYNNEOS is a third-generation vaccine licensed to prevent smallpox and mpox. The Advisory Committee on Immunisation Practices (ACIP) recommended it for individuals at risk of orthopoxvirus infections, including mpox.
Since the 2022 pox outbreak, JYNNEOS has been the primary vaccine used in the U.S. It is based on the live attenuated Modified Vaccinia Ankara (MVA) virus, which does not replicate efficiently in humans.
Mr Aina thanked the U.S. government, saying the handover was a testament to the power of international cooperation in the face of global health challenges.
The DG highlighted that this solidarity reinforced the strong bond between Nigeria and the United States, underscoring their shared commitment to global health security.
“Nigeria experienced a significant outbreak of mpox in 2022, but the recent resurgence of cases has underscored the virus’s ongoing threat,” he said.
He said the NPHCDA was committed to ensuring the vaccines were distributed equitably and efficiently to those at highest risk.
“The strategy will prioritise frontline workers, individuals with close contact with confirmed mpox cases, and vulnerable populations,” he said.
He said vaccination was just one aspect of a comprehensive approach to combating Mpox.
According to him, public awareness is also a critical component of the strategy, with plans to intensify efforts to educate the public about mpox, its symptoms, transmission routes, and preventive measures.
He called for the full cooperation of the press, including print, electronic, and new media, in empowering citizens with knowledge to reduce the risk of transmission and promote early reporting of suspected cases.